Tradjenta (Linagliptin) Patent Expiration, LOE Window & CMS Spending
Tradjenta (Linagliptin) by Boehringer Ingelheim: FDA Orange Book LOE 2037-12-08, 8 AB generics, $1.26B 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N201280 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2037-12-08 |
| Orange Book Patents (*PED Extensions) | 16 patents (8 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $1.26B |
| 2024 Medicare Part D Spend | $1.13B |
| 2024 Medicaid Spend | $137.0M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.